Operating Grant
Canadian blood cancer researchers are invited to submit proposals to The Leukemia & Lymphoma Society of Canada (LLSC)'s Operating Grant Program Competition. This is a two-year grant designed to provide funding to research that may ultimately lead to a significant change in the understanding, diagnosis, or treatment of blood cancers. The Operating Grant will provide funding up to a maximum of $100,000 per year for two years.
- Call for Proposals - October 30, 2025
- Letter of Intent (LOI) deadline - December 4, 2025, 4 pm ET
- Notification of Full Application invite - December 2025
- Full Application deadline - February 4, 2026, 4 pm ET
- Review Panel meeting - April 2026
- Notification of Awards - Summer 2026
- Award start date - Fall 2026
The application process will occur in two phases:
Phase I - Submission and consideration of a Letter of Intent (LOI).
Phase II - Invitation to submit a Full Application.
Both the Letter of Intent and the Full Application must be submitted electronically to the LLSC Research Grants portal through Proposal Central. (You must have an account on Proposal Central and be logged in.)
Applicants are welcome to contact us about eligibility or any other questions about the grant.
Funds for competitive applications will be awarded on the basis of scientific merit, using a priority rating system.
Operating Grant Funding Partners
LLSC is pleased to continue partnering with the following organizations in our Operating Grant program.
Cancer Research Society (CRS) is co-funding five operating grants in this funding cycle. The CRS is a national not-for-profit organization whose sole mission is to fund research on all types of cancer, thereby contributing to the advancement of science aimed at preventing, detecting, and treating the disease.
Cell Therapy Transplant Canada (CTTC) is co-funding one Operating Grant in this funding cycle. CTTC is a member-led, national, multidisciplinary organization providing leadership and promoting excellence in patient care, research, and education in the field of hematopoietic cell transplant and cell therapy (HCT/CT). CTTC applications should describe an innovative multicentre project that aims to improve the outcome, efficacy, and/or safety of HCT/CT in Canada.
Myeloma Canada is co-funding one Operating Grant in this funding cycle. Myeloma Canada is the only national charitable organization created by, and for, Canadians impacted by myeloma. The organization is driven to improve the lives of those affected by myeloma by empowering the community through awareness, education and advocacy programs, and supporting clinical research to find a cure. Since it was founded in 2005, Myeloma Canada has been making myeloma matter. Applications relating to the treatment of myeloma should aim to accelerate the development of Canadian academic immunotherapies.
